|
FR2160326B1
(enExample)
*
|
1971-11-19 |
1975-02-07 |
Anvar |
|
|
US4079127A
(en)
*
|
1976-10-28 |
1978-03-14 |
Board Of Regents Of The University Of Texas |
Thymosin alpha 1
|
|
US4116951A
(en)
*
|
1977-04-22 |
1978-09-26 |
Hoffmann-La Roche Inc. |
[Asn2 ]-thymosin α1 and analogs thereof
|
|
US4148788A
(en)
*
|
1978-01-23 |
1979-04-10 |
Hoffmann-La Roche Inc. |
Synthesis of thymosin α1
|
|
US4690623A
(en)
*
|
1978-05-31 |
1987-09-01 |
Karl Eickmann |
Fluid pumps, fluid motors and devices, which include a coned ring
|
|
DE2919592A1
(de)
*
|
1979-05-15 |
1981-01-15 |
Max Planck Gesellschaft |
Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
|
|
DE3100974A1
(de)
*
|
1980-01-18 |
1982-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen |
Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
|
|
US4470926A
(en)
*
|
1980-01-18 |
1984-09-11 |
Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. |
Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
|
|
US4612365A
(en)
*
|
1980-03-25 |
1986-09-16 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften |
Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
|
|
US4293455A
(en)
*
|
1980-04-07 |
1981-10-06 |
Rockefeller University |
N.sup.α -Desacetylthymosinα1 and process
|
|
IL62903A0
(en)
|
1980-05-22 |
1981-07-31 |
Deutsches Krebsforsch |
Method for the production of interferon ii and stimulated clones for the carrying out of the method
|
|
US4390623A
(en)
*
|
1980-10-02 |
1983-06-28 |
Hooper Trading Company |
Serum-free and mitogen-free T-cell growth factor and process for making same
|
|
US4475196A
(en)
*
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4464355A
(en)
*
|
1981-03-26 |
1984-08-07 |
Hooper Trading Co. |
Serum-free and mitogen-free T-cell growth factor and process for making same
|
|
US4448879A
(en)
*
|
1981-03-26 |
1984-05-15 |
Hooper Trading Company |
High yield process for in vitro production of serum-free and mitogen-free interleukin-2
|
|
US4447233A
(en)
*
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4406830A
(en)
*
|
1981-04-17 |
1983-09-27 |
Shanksville Corporation, N.V. |
Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
|
|
DE3120912A1
(de)
*
|
1981-05-26 |
1982-12-16 |
Hoechst Ag, 6000 Frankfurt |
Verfahren zur herstellung von p-nitrophenetol
|
|
US4439196A
(en)
*
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
*
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
*
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4504415A
(en)
*
|
1983-04-04 |
1985-03-12 |
Hoffman-La Roche Inc. |
Synthesis of thymosin α1 and desacetyl thymosin α1
|
|
US4486194A
(en)
*
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4614731A
(en)
*
|
1983-09-15 |
1986-09-30 |
Hoffmann-La Roche Inc. |
Peptide having immunopotentiating activity similar to thymosin alpha1
|
|
US4659694A
(en)
*
|
1983-10-27 |
1987-04-21 |
Hoffmann-La Roche Inc. |
Prothymosin alpha
|
|
US4716148A
(en)
*
|
1984-08-13 |
1987-12-29 |
Hoffman-La Roche Inc. |
Prothymosin alpha
|
|
US5643565A
(en)
*
|
1985-09-20 |
1997-07-01 |
Chiron Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5503841A
(en)
*
|
1985-09-20 |
1996-04-02 |
Cetus Oncology Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5100664A
(en)
*
|
1985-09-20 |
1992-03-31 |
Cetus Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5098702A
(en)
*
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
JPS63503308A
(ja)
|
1986-05-09 |
1988-12-02 |
スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ |
抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法
|
|
US4959217A
(en)
*
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4925678A
(en)
*
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
*
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
US5376369A
(en)
*
|
1987-11-03 |
1994-12-27 |
Syntex (U.S.A.) Inc. |
Vaccine adjuvant
|
|
SE8801426D0
(sv)
|
1988-04-15 |
1988-04-15 |
Ulf Rothman |
Forfarande och medel for blodbehandling
|
|
JP2955314B2
(ja)
*
|
1988-10-27 |
1999-10-04 |
リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ |
Ｉｌ―２含有リポソーム免疫アジュバント
|
|
US6534055B1
(en)
*
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
IL92382A
(en)
*
|
1988-11-23 |
1994-12-29 |
Univ Michigan |
Use of a ligand specific for CD28 in the manufacture of medicament
|
|
US5167616A
(en)
*
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
IT1238231B
(it)
|
1989-12-18 |
1993-07-12 |
Consiglio Nazionale Ricerche |
Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
|
|
US5830452A
(en)
*
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
|
US5225182A
(en)
*
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
KR100223255B1
(ko)
|
1992-02-10 |
1999-10-15 |
더글라스 테스타 |
개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
|
|
CA2139756A1
(en)
*
|
1992-07-08 |
1994-01-20 |
Eric M. Bonnem |
Use of gm-csf as a vaccine adjuvant
|
|
CN1094310A
(zh)
|
1992-12-15 |
1994-11-02 |
托马斯·C·梅里根 |
人体免疫缺陷性病毒感染用组合式化学疗法
|
|
US5747024A
(en)
*
|
1993-03-08 |
1998-05-05 |
Immunex Corporation |
Vaccine adjuvant comprising interleukin-15
|
|
DK0700430T3
(da)
|
1993-06-04 |
2005-08-15 |
Us Navy |
Fremgangsmåder til selektivt af stimulere proliferation af T-celler
|
|
AU686660B2
(en)
|
1993-08-11 |
1998-02-12 |
Jenner Technologies |
Prostatic cancer vaccine
|
|
CN1044781C
(zh)
|
1994-02-05 |
1999-08-25 |
丹东市生物制品免疫技术应用研究中心 |
复方免疫抗生素
|
|
DE4412794A1
(de)
*
|
1994-04-14 |
1995-12-14 |
Univ Ludwigs Albert |
Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
|
|
US5632983A
(en)
*
|
1994-11-17 |
1997-05-27 |
University Of South Florida |
Method for treating secondary immunodeficiency
|
|
EP0789588B1
(en)
|
1994-11-17 |
2005-01-19 |
University Of South Florida |
Method for making a medicament for treating secondary immunodeficiency
|
|
US5626838A
(en)
*
|
1995-03-13 |
1997-05-06 |
The Procter & Gamble Company |
Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
|
|
DE69628921T2
(de)
|
1995-05-04 |
2004-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Navy |
Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels
|
|
US5788963A
(en)
*
|
1995-07-31 |
1998-08-04 |
Pacific Northwest Cancer Foundation |
Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
|
|
NZ331369A
(en)
|
1996-02-21 |
2001-04-27 |
Franco Lori |
Use of a genetic construct that directs virus expression in a lymphoid organ or a transduced cell thereof for genetic immunization
|
|
US5849589A
(en)
*
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
US6017527A
(en)
*
|
1996-07-10 |
2000-01-25 |
Immunex Corporation |
Activated dendritic cells and methods for their activation
|
|
US5849307A
(en)
*
|
1997-03-26 |
1998-12-15 |
The Picower Institute For Medical Research |
Vaccine adjuvant
|
|
US6358508B1
(en)
*
|
1997-06-11 |
2002-03-19 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR9
|
|
AU748467B2
(en)
*
|
1997-10-17 |
2002-06-06 |
University Of South Florida |
Method to diagnose and monitor cellular immune deficiencies
|
|
ATE428769T1
(de)
*
|
1997-10-27 |
2009-05-15 |
Univ Rockefeller |
Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
|
|
PT1053017E
(pt)
*
|
1998-02-12 |
2004-12-31 |
Wyeth Corp |
Vacinas compreendendo interleucina-12 e antigenio de virus herpes simplex
|
|
US20050124645A1
(en)
*
|
1998-04-20 |
2005-06-09 |
Finkel Terri H. |
Methods and compositions for increasing CD4lymphocyte immune responsiveness
|
|
EP0974357A1
(en)
|
1998-07-16 |
2000-01-26 |
Schering-Plough |
Chemokines as adjuvants of immune response
|
|
IL125608A0
(en)
|
1998-07-30 |
1999-03-12 |
Yeda Res & Dev |
Tumor associated antigen peptides and use of same as anti-tumor vaccines
|
|
GB9827103D0
(en)
*
|
1998-12-10 |
1999-02-03 |
Onyvax Ltd |
New cancer treatments
|
|
US6017537A
(en)
*
|
1998-12-18 |
2000-01-25 |
Connaught Laboratories, Inc. |
Formyl methionyl peptide vaccine adjuvant
|
|
US6350589B1
(en)
*
|
1998-12-31 |
2002-02-26 |
Viragen, Inc. |
Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
|
|
GB9903664D0
(en)
*
|
1999-02-17 |
1999-04-14 |
Isis Innovation |
Adjuvant and cell maturation agent
|
|
US6667175B1
(en)
|
1999-06-15 |
2003-12-23 |
The Trustees Of Columbia University |
Generation of antigen specific T suppressor cells for treatment of rejection
|
|
US7056503B2
(en)
*
|
1999-08-19 |
2006-06-06 |
Regents Of The University Of Michigan |
Enclosures housing cell-coated supports for treating tumors
|
|
US6406699B1
(en)
|
1999-10-05 |
2002-06-18 |
Gary W. Wood |
Composition and method of cancer antigen immunotherapy
|
|
DK1257632T3
(da)
*
|
2000-02-24 |
2008-01-28 |
Xcyte Therapies Inc |
Samtidig stimulering og opkoncentrering af celler
|
|
CN1437481A
(zh)
*
|
2000-06-22 |
2003-08-20 |
美国氰胺公司 |
作为佐剂组合的qs－21和il－12
|
|
US20070025958A1
(en)
*
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
|
US20060194242A1
(en)
*
|
2000-10-27 |
2006-08-31 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
|
CA2950109C
(en)
|
2000-10-27 |
2019-02-19 |
John W. Hadden |
Vaccine immunotherapy for immune suppressed patients
|
|
US7182942B2
(en)
|
2000-10-27 |
2007-02-27 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy for immune suppressed patients
|
|
US20070031372A1
(en)
*
|
2004-08-05 |
2007-02-08 |
Hadden John W |
Vaccine immunotherapy for immune suppressed patients
|
|
FR2823222B1
(fr)
|
2001-04-06 |
2004-02-06 |
Merial Sas |
Vaccin contre le virus de la fievre du nil
|
|
JP2005510491A
(ja)
|
2001-10-26 |
2005-04-21 |
イミュノ−アールエックス， インコーポレイテッド |
免疫抑制を逆転させるための免疫治療
|
|
DE10154579A1
(de)
*
|
2001-11-07 |
2003-05-28 |
Medigene Ag |
Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
|
|
WO2003061566A2
(en)
|
2002-01-24 |
2003-07-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anti-cancer combination and use thereof
|
|
CA2510229A1
(en)
|
2002-12-13 |
2004-07-08 |
Aventis Pasteur, Inc. |
Production of alvac on avian embryonic stem cells
|
|
CA2511815A1
(en)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
|
CN103184234A
(zh)
|
2003-04-15 |
2013-07-03 |
圣诺菲·帕斯图尔有限公司 |
用于预防和/或治疗癌症的肿瘤抗原bfa5
|
|
US6896879B2
(en)
*
|
2003-07-03 |
2005-05-24 |
Cel-Sci Corporation |
Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
|
|
WO2005077048A2
(en)
|
2004-02-09 |
2005-08-25 |
The Johns Hopkins University |
Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
|
|
GB0409799D0
(en)
*
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
ES2553133T3
(es)
|
2004-06-04 |
2015-12-04 |
Cel-Sci Corporation |
Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor
|
|
WO2005123120A1
(en)
|
2004-06-16 |
2005-12-29 |
Smart Drug Systems Inc. |
Sustained release vaccine composition
|
|
WO2006047515A2
(en)
|
2004-10-25 |
2006-05-04 |
Baylor Research Institute |
Dendritic cells loaded with heat shocked melanoma cell bodies
|
|
US20070065415A1
(en)
|
2005-09-16 |
2007-03-22 |
Kleinsek Donald A |
Compositions and methods for the augmentation and repair of defects in tissue
|
|
EP1996013A4
(en)
|
2005-09-21 |
2010-03-10 |
Dask Technologies Llc |
METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
|
|
KR20150082688A
(ko)
|
2005-12-08 |
2015-07-15 |
노쓰웨스트 바이오써라퓨틱스, 인크. |
미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
|
|
US20070259330A1
(en)
|
2006-05-04 |
2007-11-08 |
Ge Healthcare Bio-Sciences Ab |
Separation of cells
|
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
WO2008133983A1
(en)
|
2007-04-25 |
2008-11-06 |
Immurx, Inc. |
Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
|
|
CA2691539C
(en)
*
|
2007-06-21 |
2014-08-26 |
Angelica Therapeutics, Inc. |
Modified toxins
|
|
AU2008329741B2
(en)
|
2007-11-28 |
2013-09-12 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
|
WO2009137238A2
(en)
|
2008-04-14 |
2009-11-12 |
Irx Therapeutics, Inc. |
Irx-2 modified manufacturing process
|
|
AU2009251277A1
(en)
*
|
2008-05-29 |
2009-12-03 |
Irx Therapeutics, Inc. |
Mechanism of action of primary cell derived biologic
|
|
CA3017298C
(en)
*
|
2009-05-15 |
2021-09-28 |
Irx Therapeutics, Inc. |
Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
|
|
CN103097543A
(zh)
|
2009-12-08 |
2013-05-08 |
伊尔克斯治疗有限公司 |
逆转朗格汉斯细胞免疫抑制的方法
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|